Dyslipidemia is one of the major risk factors for premature cardiovascular morbidity and mortality in the T2DM patients
[2,3]. Multiple anti-hyperglycemic and anti-hyperlipidemic drugs with different mechanisms are often needed for effective treatment of hyperlipidemic type 2 diabetic patients [4,5].